Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy

The decision to halt the study was based on the unanimous recommendation by an independent data safety monitoring committee during its routine review of the ASCENT study.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news